Medical Communications, Pharma · medium ·
Pharma M&A Increasingly Adding AI Capability Audits To Due Diligence
M&A activity in medical communications and wider pharma commercialisation is shifting towards acquiring companies that offer structured evidence generation and 'AI-ready' insight capabilities. This suggests that the ability to feed advanced AI operating layers, rather than just acquiring standalone AI tools, is becoming a key due diligence criterion for strategic acquisitions.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.